JNJ Related FDA
-
J&J's (JNJ) Janssen Receives Priority Review from FDA for Simeprevir
-
Amarin's (AMRN) Vascepa Tracking Well 3-Months In; Investors Eye Tier 2 Designation
-
Janssen-Cilag (JNJ) Submits MA to EMA for Canagliflozin, Metformin in Type 2 Diabetes
-
Idenix (IDIX) Enters Collaboration with Janssen Pharma for DAA HCV Evaluatlion
-
FDA Grants Accelerated Approval for SIRTURO (bedaquiline) For Pulmonary MDR-TB
-
Janssen (JNJ) Submits NDA for Canagliflozin to FDA
-
Janssen Approved for Expanded Indication of ZYTIGA (JNJ)
-
FDA Said to Approve Expanded Indication for Janssen's (JNJ) Zytiga
-
J&J's (JNJ) Janssen Receives FDA Panel Backing for MDR-TB Drug Bedaquiline
-
J&J's (JNJ) Experimental TB Drug Receives Unanimous FDA Panel Backing
-
J&J's (JNJ) Janssen Receives Position EMA CHMP Opinion for ZYTIGA as mCRPC Treatment
-
J&J's (JNJ) Janssen Reports Significant Phase 3 Data from Golimumab on Radiographic Progression in RA Patients
-
J&J's (JNJ) Janssen Reports Significant Findings from PSUMMIT II on Psoriatic Arthritis
-
Vertex (VRTX) Pops Higher, Enters Two New HCV Treatment Collaborations
-
J&J (JNJ) to Present New TMC435 Data on HCV at AASLD in Nov.
-
J&J's (JNJ) Janssen-Cilag Gets EC Approval for DACOGEN in AML
-
Alzheimer's Treatment Pharmas on Watch as Merz Gets Positive CHMP Opinion for Memantine MAA
-
J&J's (JNJ) Janssen Unit Submits BLA for Anti-TNF)-alpha SIMPONI
-
Johnson & Johnson (JNJ) Said to Settle Risperdal Case on First Day; Shares Move Higher
-
Johnson & Johnson's (JNJ) Janssen Granted Priority Review for TMC207 NDA
-
Leerink Swann Maintains an 'Outperform' on Medivation (MDVN); Number of Advantages Based on Labeling
-
J&J's (JNJ) Janssen Settles RISPERDAL Suit w/ 36 States and D.C.; Will Pay $181M
-
Janssen Pharmaceuticals (JNJ) Receives sNDA for NUCYNTA ER for Pain Associated with Diabetic Peripheral Neuropathy
-
Janssen (JNJ) Receives FDA Priority View for sNDA of ZYTIGA
-
Janssen Says ZYTIGA sNDA Received Priority Review Status from FDA (JNJ)
-
Elan (ELN) Updates Investors on Bapineuzumab Discontinuation
-
Johnson & Johnson (JNJ) Says Bapineuzumab IV in Alzheimer's Stopped
-
Canaccord Genuity Afternoon Coffee on PFE, ELN, and JNJ: I Just Forgot What I Was About to Say
-
Janssen, Johnson & Johnson (JNJ) to Present Data from Five Pivotal Canagliflozin Phase 3s
-
J&J (JNJ) Says FDA Issued CRL for Janssen's 800mg PREZISTA
-
J&J (JNJ) subject of $1.1 billion penalty in Risperdal trial in Arkansas
-
Canaccord Genuity Morning Coffee on Dendreon (DNDN) and Johnson & Johnson (JNJ): Honeydew Sized Prostate
-
Medivation (MDVN) Higher on Positive Data from J&J's Zytiga
-
Committee Recommends J&J's (JNJ) ZYTIGA Study Be Unblinded Amid Better Survival Data
-
Dendreon (DNDN) Smacked on Positive Data from J&J's (JNJ) Zytiga
-
Boston Scientific (BSX) Gets Favorable Ruling in Patent Case with J&J (JNJ)
-
Johnson & Johnson (JNJ) said to agree to $1 billion accord in Risperdal sales probe
-
J&J (JNJ), CR Bard (BCR) Ordered to Study Injuries from Vaginal Implants -Bloomberg
-
FDA Panel Says Benefits of J&J (JNJ) Birth Control Patch Outweigh Risks -Bloomberg
-
Pharmacyclics (PCYC) Enters PCI-32765 Collaboration w/ J&J (JNJ) Unit; to Get $150M Upfront
-
ImmunoGen (IMGN) to Discontinue IMGN388 Development, Will Refocus Resources
-
Affymax (AFFY) Settles with J&Js (JNJ) Janssen Biotech; Will Pay $13M in Fees, Milestones
-
EC Opens Investigation on J&J (JNJ) Over Fentanyl Patches (NVS)
-
Boston Scientific's (BSX) NIR Stent Found Not to Infringe on J&J's (JNJ) Fischell Patent
-
Johnson & Johnson (JNJ), Bayer Receive Favorable FDA Panel Vote for Xarelto
-
Johnson & Johnson (JNJ), Bayer Lower after Receiving Adverse Comments About Blood-Thinner, Xarelto
-
J&J's (JNJ) Depuy Orthopaedics Gets FDA 501k Clearance to Trumatch
-
J&J's (JNJ) Cordis Receives FDA Approval for Exoseal(TM) Vascular Closure Device
-
FDA Approves J&J's (JNJ) Zytiga; Dendreon (DNDN) Shares Volatile Following Announcement
-
Merck (MRK) Settles with J&J (JNJ); to Make One-Time Payment of $500M; Affirms FY11 Outlook
Back to JNJ Stock Lookup
